Akari Therapeutics (AKTX) News Today → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free AKTX Stock Alerts $1.46 -0.05 (-3.00%) (As of 10:51 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short InterestMay 10, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.comMay 10, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200 Day Moving Average of $2.47May 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday TradingMay 1, 2024 | msn.comAkari gains despite leadership change amid portfolio shakeupMay 1, 2024 | markets.businessinsider.comAkari Therapeutics Appoints Samir Patel Interim CEO After CEO Rachelle Jacques Steps DownMay 1, 2024 | globenewswire.comSamir R. Patel, M.D. Appointed Interim CEO for Akari TherapeuticsMay 1, 2024 | globenewswire.comAkari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger EntityApril 15, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 15, 2024 | globenewswire.comAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday TradingApril 12, 2024 | msn.comDindin lethal in Akari’s disposal of Capital1April 1, 2024 | finance.yahoo.comAkari Therapeutics Insider Ups Holding By 69% During YearApril 1, 2024 | globenewswire.comAkari Therapeutics Reports Full-Year 2023 Financial Results and Recent HighlightsMarch 17, 2024 | msn.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 7, 2024 | bizjournals.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 6, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 5, 2024 | businesswire.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersFebruary 27, 2024 | msn.comPVL: Grethcel Soltones, Akari still a work in progressFebruary 25, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 24, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 16, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 9, 2024 | msn.comPVL: Akari’s Max Juangco taking pressure of her pro debut in strideFebruary 7, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday TradingFebruary 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week HigherJanuary 23, 2024 | investing.comAkari Therapeutics PLC (AKTX)January 22, 2024 | msn.comPVL: Faith Nisperos, Akari Chargers aim for Final FourJanuary 2, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingDecember 16, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 45.45% to 81.60December 14, 2023 | finance.yahoo.comAkari Therapeutics to Present at Biotech Showcase 2024December 2, 2023 | investing.comAkari Therapeutics (AKTX) Earnings Dates & ReportsDecember 1, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday TradingNovember 28, 2023 | sg.finance.yahoo.comAkari Therapeutics, Plc (CLA.F)November 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher FridayNovember 16, 2023 | finance.yahoo.comAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceNovember 14, 2023 | msn.comTravel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher TuesdayNovember 6, 2023 | finance.yahoo.comAkari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceOctober 3, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference 63 Day 1 on October 4 Register NowSeptember 29, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 29, 2023 | finance.yahoo.comAkari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 27, 2023 | finance.yahoo.comAkari Therapeutics to Present at Emerging Growth ConferenceSeptember 21, 2023 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax CreditSeptember 19, 2023 | finance.yahoo.comAkari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet NeedsSeptember 5, 2023 | finance.yahoo.comAkari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 31, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10August 21, 2023 | finance.yahoo.comBritish pharma opens U.S. headquarters in BostonAugust 18, 2023 | finance.yahoo.comAkari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical TrialsAugust 17, 2023 | marketbeat.comTrading was temporarily halted for "AKTX" at 10:08 AM with a stated reason of "LULD pause." Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. AKTX Media Mentions By Week AKTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKTX News Sentiment▼0.600.56▲Average Medical News Sentiment AKTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKTX Articles This Week▼61▲AKTX Articles Average Week Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Elevai Labs News Today Moleculin Biotech News Today MIRA Pharmaceuticals News Today ABVC BioPharma News Today Eterna Therapeutics News Today Imunon News Today Molecular Templates News Today Guardion Health Sciences News Today Purple Biotech News Today Chemomab Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKTX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHow to Make 100X on the AI BoomInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.